Earnings call transcript: Planet 13 sees Q1 revenue decline amid strategic shifts

Planet 13 reported Q1 2026 revenue of $21.1 million, down from $25.2 million in Q4, but management said the decline was driven largely by one-time items tied to the California divestiture and the removal of a Florida loyalty benefit. Gross margin held at 44.6%, while Adjusted EBITDA was a $2.3 million loss and cash and restricted cash ended at $16.3 million. The more important upside catalyst is regulatory: medical marijuana was rescheduled to Schedule III, which should eliminate 280E for Planet 13's Florida operations and could materially improve future margins and cash flow.

Analysis

PLNH is less a revenue story than a tax-structure and mix-shift story. The near-term inflection is not consumer demand; it is margin math: the Florida BHO ramp plus the removal of California drag should create visible operating leverage into Q2/Q3, while the Schedule III shift creates a potentially larger, slower-burn earnings rerating if guidance starts to reflect a lower effective tax burden. That combination matters because this equity is priced like a distressed cash burner, so even modest EBITDA improvement can produce outsized multiple expansion.

The second-order winner here is not just PLNH’s Florida footprint; it is the entire compliant cannabis value chain in medical-heavy states. If 280E relief becomes durable, the advantage shifts toward operators with meaningful taxable income and cleaner accounting, while illicit/hemp overhangs compress for any retailer that can actually enforce age-gated, tested product. Conversely, smaller peers with weaker balance sheets may see the same policy change simply accelerate consolidation rather than widen industry profitability.

The main risk is timing mismatch: policy headlines can re-rate the stock before cash flow proves the story, but if Treasury/IRS guidance narrows the benefit or delays retroactive treatment, the current rally case fades quickly. Separately, the company’s real constraint is balance-sheet optionality; if Florida competitive intensity worsens or Nevada tourism softens again, the market will treat every incremental dollar of gross profit as temporary rather than durable. That makes this a 1-2 quarter catalyst trade, not a permanent compounder call.

Consensus is probably underestimating how much of the upside can come from multiples, not fundamentals. A stock near cash-burn valuation does not need heroic growth to double; it needs one or two quarters of cleaner reported numbers and a credible path to lower tax drag. The contrarian angle is that the market may still be anchoring on cannabis sector fatigue and missing that PLNH’s incremental earnings sensitivity to policy normalization is now asymmetric versus its depressed base.

Key Decisions for Investors

• Long PLNH common for a 1-2 quarter catalyst window; size small-to-medium and use a stop on any Q2 miss on Florida/BHO ramp or if cash burn re-accelerates. Risk/reward is attractive because the equity can re-rate sharply on even modest EBITDA improvement from a distressed base.
• Buy PLNH Jan-2027 call spreads rather than outright equity if liquidity allows; the trade captures regulatory optionality and tax re-rating while limiting downside if IRS/Treasury guidance is delayed. Best setup is on post-earnings pullbacks or any selloff on sector-wide weakness.
• Pair trade: long PLNH / short a higher-multiple multi-state operator with less Schedule III sensitivity. The relative trade isolates the tax-normalization upside in a name where policy relief should matter more to valuation.
• For more risk-averse exposure, wait for confirmation of Florida BHO commercialization and a second sequential improvement in operating cash flow before adding. That reduces false-start risk if the Q2 improvement is mostly narrative-driven.
• Trim or avoid if the stock approaches a full policy rerating before guidance updates the tax line; at that point the asymmetry shifts and the trade becomes vulnerable to 'sell the news' behavior.